BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Celivarone: Phase II data

The double-blind, international Phase II ALPHEE trial in 486 patients showed that once-daily doses of 50, 100 and 300 mg celivarone each missed the primary endpoint of significantly reducing the proportion of patients experiencing VT/VF-triggered ICD interventions or sudden death vs. placebo (67%, 58.8% and...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >